CY 1747

Drug Profile

CY 1747

Alternative Names: CY-1747; PB1.3

Latest Information Update: 23 Apr 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epimmune
  • Developer Epimmune; Sumitomo Pharmaceuticals
  • Class Anti-ischaemics; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cerebrovascular disorders; Ischaemic heart disorders

Most Recent Events

  • 12 Jan 1996 An animal study has been added to the Thromboses pharmacodynamics section
  • 28 Aug 1995 Discontinued-Preclinical for Cerebrovascular disorders in USA (Unknown route)
  • 28 Aug 1995 Discontinued-Preclinical for Ischaemic heart disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top